Filing Details

Accession Number:
0001127602-19-021143
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-07 17:41:53
Reporting Period:
2019-06-06
Accepted Time:
2019-06-07 17:41:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
711404 Cooper Companies Inc COO Ophthalmic Goods (3851) 942657368
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1183216 Michael Kalkstein 6140 Stoneridge Mall Drive
Suite 590
Pleasanton CA 94588
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-06 3,500 $49.57 9,838 No 4 M Indirect The Kalkstein and English Family Trust u/a/d May 18, 2005
Common Stock Disposition 2019-06-06 3,500 $316.28 6,338 No 4 S Indirect The Kalkstein and English Family Trust u/a/d May 18, 2005
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect The Kalkstein and English Family Trust u/a/d May 18, 2005
No 4 S Indirect The Kalkstein and English Family Trust u/a/d May 18, 2005
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2019-06-06 3,500 $0.00 3,500 $49.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,000 2020-10-31 No 4 M Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 0 Direct
Footnotes
  1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.2511 to $316.4611. The reporting person undertakes to provide to The Cooper Companies, Inc., any security holder of The Cooper Companies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
  2. All shares granted under this option are currently exercisable.